Skip to main content

United States News All stories

Every story in this section, newest first — page 225 of 373.

Grafa

Hoth Therapeutics preclinical data shows GDNF reprograms liver fat metabolism

Hoth Therapeutics (NASDAQ:HOTH) announced on Tuesday, April 14, 2026, positive preclinical results for its HT-VA program, showing that parenteral administration of Glial Cell-Derived Neurotrophic Factor (GDNF) can fundamentally alter liver fat metabolism.

Read more: Hoth Therapeutics preclinical data shows GDNF reprograms liver fat metabolism
Grafa
Technology

Horizon Aircraft advances Cavorite X7 development with new strategic partnerships

Horizon Aircraft (NASDAQ:HOVR) reported its third-quarter fiscal 2026 financial results on Tuesday, April 14, 2026, detailing a strengthened balance sheet and a series of manufacturing milestones intended to bring its flagship hybrid-electric aircraft to market by 2027.

Read more: Horizon Aircraft advances Cavorite X7 development with new strategic partnerships
Grafa
Transport and logistics

United, American Airlines shares climb after report of Kirby floating merger to Trump

Shares of United Airlines Holdings (NYSE:UAL) and American Airlines Group (NASDAQ:AAL) rose in premarket trading on Tuesday following reports that United CEO Scott Kirby privately pitched a potential merger of the two carriers to U.S. President Donald Trump in February.

Read more: United, American Airlines shares climb after report of Kirby floating merger to Trump
Grafa
Technology

Amazon in advanced talks to acquire Globalstar for satellite push

Amazon.com (NASDAQ:AMZN) is in advanced negotiations to acquire satellite operator Globalstar Inc., according to people familiar with the matter, a move aimed at accelerating the retail giant’s efforts to challenge Elon Musk’s SpaceX in the burgeoning satellite-broadband market.

Read more: Amazon in advanced talks to acquire Globalstar for satellite push
Grafa

IDEAYA announces positive Phase 2/3 data in metastatic uveal melanoma

IDEAYA Biosciences (NASDAQ:IDYA) and Servier reported breakthrough topline results today from the Phase 2/3 OptimUM-02 trial, demonstrating that the combination of darovasertib and crizotinib significantly improved outcomes for patients with first-line HLA-A*02:01-negative metastatic uveal melanoma (MUM).

Read more: IDEAYA announces positive Phase 2/3 data in metastatic uveal melanoma